menu search

Zevra therapeutics presents design of phase 2 clinical trial investigating kp1077 for the treatment of idiopathic hypersomnia (ih) at beyond sleepy 2023

Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) — Zevra Th...

June 3, 2023, 11:30 am

Kempharm to develop kp1077 as lead sdx candidate for chronic sleep disorder

KemPharm Inc (NASDAQ: KMPH) has selected kp1077 for idiopathic hypersomnia (IH) as its lead serdexmeth...

January 20, 2022, 7:00 am

Kempharm to develop kp1077 as lead sdx candidate for chronic sleep disorder

KemPharm Inc (NASDAQ: KMPH) has selected kp1077 for idiopathic hypersomnia (IH) as its lead serdexmeth...

January 20, 2022, 7:00 am

Kempharm to develop kp1077 as lead sdx candidate for chronic sleep disorder

KemPharm Inc (NASDAQ: KMPH) has selected kp1077 for idiopathic hypersomnia (IH) as its lead serdexmeth...

January 20, 2022, 7:00 am


Search within

Pages Search Results: